ruxolitinib (Compound)

Synonyms:Ruxolitinib, 941678-49-5, INCB018424, Ruxolitinib (INCB018424), INCB-018424, (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, INCB 018424, INC424, (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, 82S8X8XX8H, CHEBI:66919, (R)-ruxolitinib, INC-424, (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile, INCB-18424, (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile, INCB18424, R-Ruxolitinib, (3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile, Ruxolitinib [INN], Ruxolitinib [USAN:INN], UNII-82S8X8XX8H, INCB 18424, INC 424, (3R)-3-CYCLOPENTYL-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PYRAZOL-1-YL)PROPANENITRILE, RXT, RUXOLITINIB [MI], Ruxolitinib (USAN/INN), INCB18424,Ruxolitinib, RUXOLITINIB [USAN], RUXOLITINIB [VANDF], RUXOLITINIB [WHO-DD], SCHEMBL171319, GTPL5688, INCB018424 - Ruxolitinib, CHEMBL1789941, SCHEMBL16546708, HSDB 8259, DTXSID10240930, ACT06813, AMY24152, EX-A1670, BDBM50355501, MFCD12031592, NSC763371, NSC800874, s1378, AKOS016842401, BCP9000784, CCG-264889, CS-0864, DB08877, NSC-763371, NSC-800874, NCGC00244253-01, NCGC00244253-02, NCGC00244253-11, NCGC00244253-12, AC-24280, AS-18619, HY-50856, A14955, A23578, D09959, AB01565782_02, EN300-18772174, Q7383611, BRD-K53972329-001-02-1, BRD-K53972329-001-03-9, (3R)-3-cyclopentyl-3-[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile, (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H -pyrazol-1-yl)-3-cyclopentylpropanenitrile, 3-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(beta-R)-1H-pyrazole-1-propanenitrile, A-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(AR)-1H-pyrazole-1-propanenitrile, (3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;Ruxolitinib, 1H-PYRAZOLE-1-PROPANENITRILE, .BETA.-CYCLOPENTYL-4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (.BETA.R)-, 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-

Pubchem:PUBCHEM:25126798

Id:6d0300b5-b596-569c-a099-dde2f35bea78

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ruxolitinib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ruxolitinib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ruxolitinib.

Results found

Linked to

	Label	Description
	BRD-K53972329-001-03-9 Substance (Entity type)	A Substance
	ruxolitinib (375a1dc1-126c-4416-9fbf-e2613d5ea5dc) Collection (Entity type)	Metadatata for ruxolitinib
	DCSTRUCT ID 04190 Collection (Entity type)	DrugPage Collection: (DrugCentralID:04190; PubChem_CID:25126798, FILE=drugcentral_drug_04190.json)
	ruxolitinib negatively regulates IFI27 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	ruxolitinib positively regulates FASN Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	ruxolitinib positively regulates SFRP1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	ruxolitinib negatively regulates S100P Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	ruxolitinib positively regulates CA2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	ruxolitinib positively regulates COL15A1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	ruxolitinib in similarity relationship with BMS-540215 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS